While autophagy is difficult to measure in vivo due to its dynamic nature and lack of reliable markers, it would be interesting to determine if GCN2−/− sarcomas have a reduced ability to undergo autophagy and if this deficiency could be therapeutically exploited in combination with GCN2 inhibition. Here, EIF2AK4 is linked to sarcoma.